An interventional study of Workplace convergence dialogue and Care Manager in Depressive Disorder and Anxiety Disorders, sponsored by Göteborg University. Active, not recruiting at 1 site in Sweden. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2024-04-05.
Sponsored by Göteborg University · Not applicable, Interventional, and Treatment
This study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the Primary Care Centre Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with a Care Manager during the period of sick leave. The study will be performed as a randomised controlled trial with randomisation at the PCC level where intervention PCCs offers a convergence dialogue meeting with the work place representative during sick leave in addition to Care Manager contact.
In Sweden sick leave time and frequency are increasing. This is primarily in the area of common mental disorders (CMD), and CMD is now the most common single cause of sickness absence. Primary care is the area in which most individuals with mental illness seek care and also receive care. A Care Manager function at the primary care centre (PCC) where the Care Manager is responsible for the support and close contact with patients with CMD and act as the "spider in the web" and combine patient support with other measures, have been shown to have beneficial effects for depression course. In Region Västra Götaland an implementation of the Care Manager function at the PCC has been set out, and the function is now available in nearly 100 PCCs in the region. The present study aims to evaluate whether a convergence dialogue during sick leave, between the employee and the employer, with the PCCs Rehab Coordinator as discussion leader, leads to reduced sick leave time compared to those individuals who only have contact with the Care Manager during the period of sick leave. The study will be performed as pragmatic randomised controlled trial with randomisation at the PCC level. Around 20 PCCs with a Care Manager function for patients on sick-leave with CMD diagnosis will be recruited and randomized to intervention where patients in addition to a Care Manager contact (12 weeks) will have one convergence dialogue meeting with the work place representative during sick leave. Control PCCs will give Care Manager contact 12 weeks only.
Patients attending primary care centers with care manager function
Exclusion Criteria:
Intervention: Work place convergence dialogue contact
Behavioral: Workplace convergence dialogue · Behavioral: Care Manager
Intervention: Care Manager contact 12 weeks (Care as usual)
Behavioral: Care Manager
Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
Regular contact Care Manager during around 12 weeks
Net and gross sick-leave days
number of net and gross sick-leave days during 12 months
Time frame: 12 months
Depressive symptoms
Change of depressive symptoms Montgomery-Asberg Depression Rating Scale - Self rating version (MADRS-S) Range 0-60 (Total score) Low score better outcome
Time frame: 6 and 12 months
Anxiety symptoms
Change of anxiety symptoms Generalized Anxiety Disorder 7-item (GAD-7) scale Range 0-15 (total score) low score better outcome
Time frame: 6 and 12 months
Quality-of-life questionnaire score
Change of quality of life EuroQoL-5 Dimension Questionnaire(EQ-5D) Range 0-1.0(total score) low score worst outcome
Time frame: 6 and 12 months
Work ability
Change of work ability Work Ability Index (WAI) Range 7-49 (total score) low score worst outcome
Time frame: 6 and 12 months
Exhaustion
Change of Exhaustion Karolinska Exhaustion Disorder Scale (KEDS) Range 0-54 (total score) low score better outcome
Time frame: 6 and 12 months
Plan to share: Yes — De-identified data of individual participants will be made available to other researchers, provided reasonable request by personal contact, as soon as publication of results is effected.
Supporting information: Study protocol, Icf, Csr
This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Göteborg University